- A US District Court in New Jersey has declared US Patent No 5,016,652, which relates to a transdermal nicotine system and is exclusively licensed to Ciba-Geigy, as invalid. The ruling came in a suit filed by Ciba-Geigy claiming that the Nicoderm patch developed by Alza and marketed by Marion Merrell Dow infringed this patent. The court's decision was due to the fact that the method used for delivering nicotine through a patch was discussed in a scientific publication more than a year before the patent was filed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze